Compile Data Set for Download or QSAR
Report error Found 57 Enz. Inhib. hit(s) with all data for entry = 11510
TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621789(US20230312522, Compound 55)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621791(US20230312522, Compound 57)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621785(US20230312522, Compound 51)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621786(US20230312522, Compound 52)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621788(US20230312522, Compound 54)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621735(US11802122, Example 1A | US20230312522, Compound 1...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621735(US11802122, Example 1A | US20230312522, Compound 1...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621773(US20230312522, Compound 39)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621769(US20230312522, Compound 35)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621772(US20230312522, Compound 38)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621781(US20230312522, Compound 47)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621777(US20230312522, Compound 43)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621780(US20230312522, Compound 46)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621757(US20230312522, Compound 24)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621759(US20230312522, Compound 26)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621753(US20230312522, Compound 20)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621755(US20230312522, Compound 22)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621756(US20230312522, Compound 23)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621765(US20230312522, Compound 31)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621766(US20230312522, Compound 33)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621767(US20230312522, Compound 34)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621761(US20230312522, Compound 28)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621762(US20230312522, Compound 29)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621764(US20230312522, Compound 32)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621741(US11802122, Example 4A | BDBM621799 | US2023031252...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621741(US11802122, Example 4A | BDBM621799 | US2023031252...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621743(US11802122, Example 5A | BDBM621800 | US2023031252...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621737(US11802122, Example 2A | US20230312522, Compound 2...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621739(US11802122, Example 3A | US20230312522, Compound 3...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621749(US20230312522, Compound 13)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621750(US20230312522, Compound 14)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621751(US20230312522, Compound 18)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621752(US20230312522, Compound 19)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621746(US11802122, Example 7A | US20230312522, Compound 1...)
Affinity DataIC50: 100nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621758(US20230312522, Compound 25)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621760(US20230312522, Compound 27)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621754(US20230312522, Compound 21)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621787(US20230312522, Compound 53)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621763(US20230312522, Compound 30)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621774(US20230312522, Compound 40)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621775(US20230312522, Compound 41)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621743(US11802122, Example 5A | BDBM621800 | US2023031252...)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621776(US20230312522, Compound 42)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621770(US20230312522, Compound 36)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621771(US20230312522, Compound 37)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621782(US20230312522, Compound 48)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621783(US20230312522, Compound 49)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621784(US20230312522, Compound 50)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621745(US20230312522, Compound 12 | US11802122, Example 6)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

TargetCholesterol 24-hydroxylase(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM621778(US20230312522, Compound 44)
Affinity DataIC50: 550nMAssay Description:Briefly, in a 384-well plate format, 10 uL per well of an enzyme-substrate mixture of CYP46A1 (5 uM final concentration) and Testosterone (10 mM fina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
US Patent

Displayed 1 to 50 (of 57 total ) | Next | Last >>
Jump to: